Overview

Acamprosate and Methazolamide for Essential Tremor

Status:
WITHDRAWN
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an investigator initiated study is designed to evaluate the anti-tremor benefits of two marketed medications, methazolamide and acamprosate in subjects with a diagnosis of essential tremor (ET).
Phase:
PHASE2
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Acamprosate
Methazolamide